CSTL vs VCYT
CSTL: Castle Biosciences provides specialized molecular diagnostic tests to improve risk stratification and personalized treatment decisions for patients with skin cancers, Barrett's esophagus, and atopic dermatitis. VCYT: Veracyte is a genomics-focused diagnostics company providing high-value clinical tests to improve cancer detection and treatment guidance for patients worldwide.
Side-by-side fundamentals
| Metric | CSTL | VCYT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.81 | $58.01 | |
| Market cap as of 2026-07-23 | $749M | $4.8B | |
| P/E as of 2026-07-23 | n/a | 53.97 | |
| PEG as of 2026-07-23 | -0.49 | 0.34 | CSTL lower |
| Net margin as of 2026-07-23 | -3.8% | +16.3% | VCYT higher |
| Gross margin as of 2026-07-23 | +77.9% | +70.9% | CSTL higher |
| Operating margin as of 2026-07-23 | -9.8% | +15.1% | VCYT higher |
| ROE as of 2026-07-23 | -2.8% | +6.9% | VCYT higher |
| ROA as of 2026-07-23 | -2.3% | +6.3% | VCYT higher |
| Debt / equity as of 2026-07-23 | 0.03 | 0.00 | VCYT lower |
| Revenue growth (YoY) as of 2026-07-23 | -2.1% | +16.9% | VCYT higher |
| Revenue CAGR (3y) SEC XBRL | +35.9% | +20.4% | CSTL higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.02 | 1.94 | |
| 1-year return as of 2026-07-22 close | +52.0% | +146.7% | VCYT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.